Bris­tol-My­ers’ check­point star Op­di­vo fails a PhI­II study for glioblas­toma

Bris­tol-My­ers Squibb $BMY has had an­oth­er set­back on the check­point in­hi­bi­tion front, though this one they can take in stride.

Their big drug Op­di­vo failed to beat out Avastin in treat­ing re­cur­rent glioblas­toma, or brain can­cer, in im­prov­ing over­all sur­vival rates. In­ves­ti­ga­tors are hold­ing back the ac­tu­al da­ta for a pre­sen­ta­tion at an up­com­ing con­fer­ence in Zurich.

Check­mate-143 was the first ran­dom­ized study of a PD-1 check­point for glioblas­toma, says Bris­tol-My­ers, which is still pur­su­ing two first-line GBM clin­i­cal tri­als, Check­Mate -498 and Check­Mate -548, eval­u­at­ing the com­bi­na­tion of Op­di­vo with ra­di­a­tion ther­a­py with or with­out temo­zolo­mide in O6-methyl­gua­nine-DNA methyl­trans­ferase (MGMT)-un­methy­lat­ed and methy­lat­ed pa­tients.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER